D-1095-2023 Class III Ongoing

Recalled by Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

FDA drug recall D-1095-2023 was initiated by Glenmark Pharmaceuticals Inc., USA on Aug 14, 2023 and is designated Class III. Reason for recall: Subpotent: Out of Specification for Assay Test at the 3-month time point. The recall status is ongoing. Affected quantity: 1,200 bottles.

Recall details

Product Type
Drugs
Report Date
Aug 30, 2023
Initiation Date
Aug 14, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,200 bottles

Product description

Trandolapril and Verapamil Hydrochloride Extended-Release Tablets 2 mg / 180 mg, 100-count Bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale -Bardez, Goa 403513, India, Manufactured for Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-295-01

Reason for recall

Subpotent: Out of Specification for Assay Test at the 3-month time point.

Distribution pattern

nationwide in the U.S.

Code information

Batch # 19224744

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1095-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1095-2023. Report a data issue: hello@regdatalab.com.